Quantum BioPharma Ltd. (QNTM) Initiates Phase 2 Lucid-MS Start-Up With Thermo Fisher

Quantum BioPharma (QNTM) partnered with Thermo Fisher to conduct a Phase 2 trial for its MS drug Lucid-MS, which targets demyelination. The trial marks a key milestone for QNTM, as it aims to offer an alternative to existing immune-focused MS treatments.

Quantum BioPharma (QNTM) has partnered with Thermo Fisher's clinical research business to initiate a Phase 2 trial for its Lucid-MS treatment, which targets demyelination in a novel neuroprotective approach. Thermo Fisher's expertise in central nervous system studies supports the trial's execution.

Quantum BioPharma (QNTM) partnered with Thermo Fisher Scientific's clinical research unit to begin Phase 2 trials for Lucid-MS, its lead multiple sclerosis treatment. This agreement is a key step in the drug's development process.

Quantum BioPharma (QNTM) partnered with Thermo Fisher to launch a Phase 2 trial for Lucid-MS, a drug candidate for progressive multiple sclerosis. The trial follows FDA clearance and aims to target demyelination, a novel approach in MS treatment. Lucid-MS has shown promise in preclinical and Phase 1 trials, with a favorable safety profile. The MS therapeutics market is projected to exceed $38 billion by 2030, according to Grand View Research.

Quantum BioPharma (QNTM) has partnered with Thermo Fisher Scientific to begin Phase 2 trials for Lucid-MS, a treatment for progressive multiple sclerosis. The FDA has cleared the trial, which will assess efficacy, safety, and tolerability. Thermo Fisher will provide clinical research services. Success could offer a new treatment option for MS, a condition with limited therapies. Quantum owns 19.84% of Unbuzzd Wellness and receives royalties from it.

Quantum BioPharma (QNTM) has initiated a Phase 2 trial for Lucid-MS, a treatment for progressive multiple sclerosis. The study will assess efficacy, safety, and tolerability. Quantum owns 19.84% of Unbuzzd Wellness and receives royalties from its UNBUZZD product.